Anti-Monkeypox and Vaccinia A13 protein [11F7]

Absolute Antibody

Anti-Monkeypox and Vaccinia A13 protein [11F7]

7

The original IgG2a version of this antibody bound to recombinant A13 protein expressed in E. coli, MBP conjugated VACV A13 in an ELISA. The original IgG2a antibody bound recombinant A13 proteins from E. coli with an affinity of 3.4 nM as detected by surface plasmon resonance. This antibody was also capable of recognizing a 12-kda protein in a Western blot of VACV-infected HeLa cells. This antibody stained viral factories and virion-size particles in immunofluorescence analysis of infected cells. This antibody was also reported to neutralized VACV mature virions in a plaque reduction assay. Passive immunization of mice with this antibody protected mice against intranasal VACV infection. This antibody generated against smallpox vaccine might contribute to immune protection against orthopoxviruses (PMID: 21810533). In Q3 of 2024, the WHO declared monkeypox a Public Health Emergency of International Concern. This product serves as a powerful tool for related research efforts.

ImmunoFluorescence, Western Blot, ELISA, Neutralisation/Blocking, Other Application

ELISA; WB; IF; SPR; neutralize

Research Use Only

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format for improved compatibility with existing reagents assays and techniques.

-20°C,2°C to 8°C

12352203